Home > Insider Trading > Filing (0000899243-20-018358)

Filing Details

Accession Number:: 0000899243-20-018358
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-02 19:19:45
Reporting Period:: 2020-07-01

Accepted Time:: 2020-07-02 19:19:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1060736	Seattle Genetics Inc	SGEN	Biological Products, (No Disgnostic Substances) (2836)	911874389

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1216477	E Todd Simpson	21823 30Th Drive Se Bothell WA 98021	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-07-01	1,300	$165.86	173,454	No	4	S	Direct
Common Stock	Disposition	2020-07-01	4,112	$166.99	169,342	No	4	S	Direct
Common Stock	Disposition	2020-07-01	5,012	$167.66	164,330	No	4	S	Direct
Common Stock	Disposition	2020-07-01	139	$170.18	164,191	No	4	S	Direct
Common Stock	Disposition	2020-07-01	1,010	$171.39	163,181	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Reflects sales of common stock executed in multiple transactions at prices ranging from $165.37 to $166.28. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported.
Reflects sales of common stock executed in multiple transactions at prices ranging from $166.49 to $167.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $167.51 to $168.05. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $171.25 to $172.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.